Viking Therapeutics reports 15% weight loss in phase 2 obesity treatment trials, targeting $100B market by 2030.
Viking Therapeutics (VKTX) specializes in developing obesity treatments using dual GIP/GLP-1 receptor agonists, with promising phase 2 results showing up to 15% weight loss. The obesity drug market is rapidly expanding, projected to reach $100 billion by 2030. Viking has a strong cash reserve of over $900 million and is also exploring treatments for NASH and X-ALD. While its stock has shown volatility, analysts suggest other investment options may be more favorable.
October 12, 2024
3 Articles